Recurrent C. difficile Infection: Expert Perspectives on Impacting Clinical Outcomes and Economics
Sponsored by The Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an education grant from Merck & Company.
Scroll to the Bottom of this Information to Begin this Course
Release date: June 30, 2017
Valid through: June 30, 2018
Specialty: Gastroenterology, Infectious Disease, Internal Medicine, Emergency Medicine, Surgery, Primary Care, Geriatrics, Critical/Intensive Care
Topic: C. difficile Infection
Estimated Time to Complete Activity: 30 minutes
This activity is intended for gastroenterologists, infectious disease specialists and other healthcare professionals that treat C. diff infections.
Clostridium difficile infection (CDI) is associated with significant morbidity and mortality. Further, recurrence of CDI is common after an initial episode. Although a number of therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. Clinicians require up-to-date knowledge of evidence-based treatment of initial and recurrent CDI to reduce its burden and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
- Identify patients who may be at increased risk for recurrent C. diff infection
- Assess the clinical efficacy and safety of biologics for prevention of recurrent CDI
- Outline evidence-based approaches for the management of first, second, and third recurrences of C. diff in diverse patient populations
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
David Binion, MD
Professor of Medicine
Clinical and Translational Research
Co-Director, IBD Center – Translational Research
Director, Nutrition Support Service
Division of Gastroenterology, Hepatology, and Nutrition
University of Pittsburgh
UPMC Presbyterian Hospital
James Lewis, II, PharmD, FIDSA
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Physician Continuing Medical Education
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education(ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
- Consulting Agreements: AbbVie, Janssen Biotech, and Synthetic Biologics, Inc.
- Grants/Research Support: Merck & Company, Shire, and UCB Pharma
- Consulting Agreements: Accelerate Diagnostics, Achaogen, Allergan, Astellas, Merck & Company, and The Medicines Company
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online activity, and complete the post-test and evaluation. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions about this activity, please contact Katlyn Cooper at firstname.lastname@example.org.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
The faculty may discuss novel therapies under investigation for the treatment of CDI.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.